Stoke Therapeutics (STOK) has reported FY 2025 results that feature a wide range of quarterly outcomes. Q1 revenue was US$158.6 million with EPS of US$1.95, followed by Q2 revenue of US$13.8 million and an EPS loss of US$0.40, and Q3 revenue of US$10.6 million with an EPS loss of US$0.65. Over recent periods the company has seen revenue move between US$4.8 million and US$158.6 million per quarter, while EPS has shifted from a US$2.07 loss in FY 2024 to a US$1.95 profit and then back into quarterly losses in FY 2025. This pattern gives investors a view of how sensitive margins are to revenue changes. Overall, these results put the spotlight on how consistently Stoke can convert its revenue base into profitability and margin stability.

See our full analysis for Stoke Therapeutics.

With the headline numbers laid out, the next step is to see how this earnings profile compares with the main narratives investors already follow about Stoke Therapeutics and where those narratives might need to be reconsidered.

TTM profit of US$40.6m contrasts with recent quarterly losses

• On a trailing 12 month basis, Stoke shows net income of US$40.6 million and EPS of US$0.70, even though the most recent quarter reported a net loss of US$38.3 million and a basic EPS loss of US$0.65.
• Consensus narrative points out that the company has moved into profitability over the past year, and this tension between a profitable trailing 12 month picture and recent quarterly losses is important for you to weigh:
  • Trailing 12 month revenue of US$205.6 million and net income of US$40.6 million contrast with Q3 FY 2025 revenue of US$10.6 million and a net loss of US$38.3 million, which leans into the idea that results can look very different depending on the time frame you focus on.
  • At the same time, five year earnings growth of 17.1% per year in the data sits alongside this latest quarterly loss, so if you lean on the consensus view you are effectively accepting that a lumpy path can still sit within a longer term growth story.

High forecast growth meets a 47.9x P/E

• The data show forecast earnings growth of about 68.8% per year and revenue growth of about 58.9% per year, while the current P/E of 47.9x sits below a 67.5x peer average and above the 20.6x US Biotechs industry average.
• Supporters of the bullish narrative often highlight those high forecast growth rates, but the current valuation mix gives you a more nuanced picture:
  • On one side, expected earnings growth above 60% per year, plus the shift to profitability over the last year, heavily supports a bullish case that the current 47.9x P/E could be paying for growth that is already visible in the numbers.
  • On the other side, the same 47.9x P/E is more than double the broader industry’s 20.6x, so even with strong forecasts the stock is not cheap relative to many other US biotech names, which is exactly the type of trade off bullish investors need to be comfortable with.

A lot of the optimistic chatter around Stoke leans on these growth forecasts and how they could reshape the story over the next few years, so if you want to see how bullish investors join the dots from drug pipeline to future earnings, 🐂 Stoke Therapeutics Bull Case

DCF fair value of US$271.73 versus a US$32.87 share price

• The DCF fair value in the data is US$271.73 per share, which is very large compared with the current share price of US$32.87, and the company is described as trading about 87.9% below that DCF estimate.
• Bears point out that, even with this wide DCF gap, traditional valuation markers still look demanding and could limit how quickly the market closes that distance:
  • Critics highlight that, although the stock trades below a peer P/E of 67.5x, it still carries a premium to the US Biotechs industry on 20.6x, so anyone focusing on sector level multiples may see less room for rerating than the DCF suggests.
  • What also stands out is that the current share price is far below both the US$271.73 DCF fair value and the single allowed analyst target of US$42.70, so bearish investors tend to question whether the assumed growth and margins behind those values can hold against recent quarterly losses such as the US$38.3 million Q3 FY 2025 result.

Skeptical investors often focus on this gap between a rich DCF and a premium P/E against the wider industry, so if you want to see the arguments that question how much of that upside is realistic, 🐻 Stoke Therapeutics Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Stoke Therapeutics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

These mixed signals around earnings, valuation, and forecasts leave plenty of room for different views, so move quickly, review the details, and shape your own stance by checking the 3 key rewards.

See What Else Is Out There

The mix of quarterly losses, a 47.9x P/E premium to the broader US biotech industry, and reliance on optimistic growth assumptions highlights meaningful earnings and valuation risk.

If that level of uncertainty feels uncomfortable, you can quickly refocus on companies where earnings and balance sheets look more resilient by checking out the 77 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.